Factors associated with successful electrical cardioversion for atrial fibrillation
Naoya Kataoka, Teruhiko Imamura

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAtrial Fibrillation Management and Outcomes · Cardiac Arrhythmias and Treatments · Cardiac electrophysiology and arrhythmias
To The Editor,
Electrical cardioversion is occasionally employed in routine clinical practice for the management of atrial fibrillation (AF). Its success is associated with the avoidance of hospitalization. The authors have identified several predictors of AF recurrence following electrical cardioversion, such as nonhigh‐density lipoprotein cholesterol (non‐HDL C) and the number of cardioversions1; however, several important considerations warrant discussion.
Given the retrospective nature of the study, the scenario of electrical cardioversion likely varied across patients. For example, clinicians may have administered antiarrhythmic agents prior to performing electrical cardioversion, particularly in symptomatic individuals. Such pharmacologic pre‐treatment could increase the likelihood of achieving and maintaining sinus rhythm.2
Definitions of successful cardioversion differ across studies. In investigations examining the role of pre‐ablation electrical cardioversion, success has been defined as the absence of AF recurrence within 24 hours.3 In contrast, this study reports that 81 patients remained free from AF recurrence over a median follow‐up period of 60 months—a markedly favorable outcome that surpasses that of contemporary catheter ablation strategies.1
Recent literature has introduced the concept of “acute atrial fibrillation,” which arises secondary to acute systemic illnesses.4 In these cases, AF may resolve entirely without recurrence following elimination of the precipitating factor. It is conceivable that patients with this self‐limited form of AF were included among those deemed successfully treated in this study.
The authors propose an association between non‐HDL‐C, chronic inflammation, and AF recurrence.1 However, the specific mechanistic link between non‐HDL‐C levels and myocardial inflammation remains unclear. Previous studies have demonstrated a relationship between AF and chronic inflammation or chronic myocardial injury, as indicated by elevated serum levels of high‐sensitivity C‐reactive protein or troponin.5, 6 Typically, elevated non‐HDL‐C is associated with coronary artery disease, which itself may confound the observed relationship with recurrent AF. Analyzing the correlation between non‐HDL‐C levels and serum inflammatory markers or troponin may clarify the relationship among these parameters.
FUNDING INFORMATION
None.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Pay L , Tezen O , Çetin T , Yumurtaş A , Keskin K , Dereli Ş , et al. Investigation of predictive parameters for recurrence in patients undergoing electrical cardioversion for atrial fibrillation. J Arrhythm. 2025;41:e 70053. 10.1002/joa 3.70053 40177525 PMC 11962753 · doi ↗ · pubmed ↗
- 2El Amrani A , Viñolas X , Arias MA , Bazan V , Valdovinos P , Alegret JM . Pharmacological cardioversion after pre‐treatment with Antiarrythmic drugs prior to electrical cardioversion in persistent atrial fibrillation: impact on maintenance of sinus rhythm. J Clin Med. 2021;10:10. 10.3390/jcm 10051029 PMC 795896033802253 · doi ↗ · pubmed ↗
- 3Kamada H , Mori K , Ueda N , Wakamiya A , Nakajima K , Kamakura T , et al. Impact of pre‐ablation direct current cardioversion for persistent atrial fibrillation to predict recurrence of atrial fibrillation after catheter ablation. Int Heart J. 2022;63:828–836. 10.1536/ihj.22-135 36184544 · doi ↗ · pubmed ↗
- 4Chyou JY , Barkoudah E , Dukes JW , Goldstein LB , Joglar JA , Lee AM , et al. Atrial fibrillation occurring during acute hospitalization: a scientific Statement from the American Heart Association. Circulation. 2023;147:e 676–e 698. 10.1161/cir.0000000000001133 36912134 · doi ↗ · pubmed ↗
- 5Ihara K , Sasano T . Role of inflammation in the pathogenesis of atrial fibrillation. Front Physiol. 2022;13:862164. 10.3389/fphys.2022.862164 35492601 PMC 9047861 · doi ↗ · pubmed ↗
- 6Kaura A , Arnold AD , Panoulas V , Glampson B , Davies J , Mulla A , et al. Prognostic significance of troponin level in 3121 patients presenting with atrial fibrillation (the NIHR health informatics collaborative TROP‐AF study). J Am Heart Assoc. 2020;9:e 013684. 10.1161/jaha.119.013684 32212911 PMC 7428631 · doi ↗ · pubmed ↗
